研究原脂蛋白基因型態對高脂血症病人藥物治療的關連(3/3)
Other Title
Studies of Apolipoprotein Genotyping on the Drug Treatment of
Hyperlipidemic Patients (3/3)
Hyperlipidemic Patients (3/3)
Date Issued
2005
Date
2005
Author(s)
陳明豐
DOI
932314B002016
Abstract
Atherosclerotic cardiovascular diseases are multi-factorial. Some
non-modifiable risk factors (e.g. genetic trait) may attenuate the benefit of
risk modification of the modifiable factors. Genetic epidemiology has
being widely used to analyze the underline risk of cardiovascular disease
and to point the direction of treatment or prevention. The genetic
variation or mutation of apolipoprotein, the protein of lipoprotein, has
been linked to some lipid abnormality resulting severe atherosclerotic
cardiovascular disease. In the present study, the genetic variation or
mutation of Apo AI-CIII-AIV cluster, Apo A-II, Apo B and Apo E were
analyzed and the correction of these mutation and lipid abnormality were
explored. Our results showed ApoC-III (3175NT C →G) mutation was
significantly related to hypertriglyceridemia, the same relation was also
found in the Apo B exon 29 (13132 NT C →G; 4311 AA Asn →Ser)
mutation. It is interesting to find some hot spot mutation among
Caucasian population, such as Apo B exon 26 (10699 NT C →A; 3500
AA Arg →Gln), Apo A-IV (1527-2345 NT) and Apo E exon 2 mutations,
were not found in tested samples. Most of presented allele frequencies in
apolipoteins genes were different between our population and Caucasian
population. The present results strongly suggest that it is necessary to
establish our own genetic data which are linked to diseases.
SDGs
Publisher
臺北市：國立臺灣大學醫學院內科
Type
report
File(s)![Thumbnail Image]()
Loading...
Name
932314B002016.pdf
Size
207.92 KB
Format
Adobe PDF
Checksum
(MD5):bdca58012cca3e81d43fd9606b6a2226